These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25809543)

  • 1. Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.
    Tancredi R; Zambelli A; DaPrada GA; Fregoni V; Pavesi L; Riccardi A; Burdach S; Grohar PJ; D'Incalci M
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1317-20. PubMed ID: 25809543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
    Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
    Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
    Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ
    Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
    Harlow ML; Maloney N; Roland J; Guillen Navarro MJ; Easton MK; Kitchen-Goosen SM; Boguslawski EA; Madaj ZB; Johnson BK; Bowman MJ; D'Incalci M; Winn ME; Turner L; Hostetter G; Galmarini CM; Aviles PM; Grohar PJ
    Cancer Res; 2016 Nov; 76(22):6657-6668. PubMed ID: 27697767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER; Pishas KI; Saund RS; Lessnick SL
    Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.
    Grohar PJ; Glod J; Peer CJ; Sissung TM; Arnaldez FI; Long L; Figg WD; Whitcomb P; Helman LJ; Widemann BC
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):645-652. PubMed ID: 28735378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H
    Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
    Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
    Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner.
    Harlow ML; Chasse MH; Boguslawski EA; Sorensen KM; Gedminas JM; Kitchen-Goosen SM; Rothbart SB; Taslim C; Lessnick SL; Peck AS; Madaj ZB; Bowman MJ; Grohar PJ
    Clin Cancer Res; 2019 Jun; 25(11):3417-3429. PubMed ID: 30723142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth.
    Gierisch ME; Pedot G; Walser F; Lopez-Garcia LA; Jaaks P; Niggli FK; Schäfer BW
    Sci Rep; 2019 Jan; 9(1):951. PubMed ID: 30700749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.
    Kovar H; Amatruda J; Brunet E; Burdach S; Cidre-Aranaz F; de Alava E; Dirksen U; van der Ent W; Grohar P; Grünewald TG; Helman L; Houghton P; Iljin K; Korsching E; Ladanyi M; Lawlor E; Lessnick S; Ludwig J; Meltzer P; Metzler M; Mora J; Moriggl R; Nakamura T; Papamarkou T; Radic Sarikas B; Rédini F; Richter GH; Rossig C; Schadler K; Schäfer BW; Scotlandi K; Sheffield NC; Shelat A; Snaar-Jagalska E; Sorensen P; Stegmaier K; Stewart E; Sweet-Cordero A; Szuhai K; Tirado OM; Tirode F; Toretsky J; Tsafou K; Üren A; Zinovyev A; Delattre O
    Oncotarget; 2016 Feb; 7(8):8613-24. PubMed ID: 26802024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors.
    Li Y; Li X; Fan G; Fukushi J; Matsumoto Y; Iwamoto Y; Zhu Y
    Cancer Lett; 2012 Jul; 320(1):14-22. PubMed ID: 22266186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma.
    Huang L; Nakai Y; Kuwahara I; Matsumoto K
    Cancer Res; 2012 Mar; 72(5):1260-9. PubMed ID: 22241085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma.
    Seong BKA; Dharia NV; Lin S; Donovan KA; Chong S; Robichaud A; Conway A; Hamze A; Ross L; Alexe G; Adane B; Nabet B; Ferguson FM; Stolte B; Wang EJ; Sun J; Darzacq X; Piccioni F; Gray NS; Fischer ES; Stegmaier K
    Cancer Cell; 2021 Sep; 39(9):1262-1278.e7. PubMed ID: 34329586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma hydrogenated cationic detonation nanodiamonds efficiently deliver to human cells in culture functional siRNA targeting the Ewing sarcoma junction oncogene.
    Bertrand JR; Pioche-Durieu C; Ayala J; Petit T; Girard HA; Malvy CP; Le Cam E; Treussart F; Arnault JC
    Biomaterials; 2015 Mar; 45():93-8. PubMed ID: 25662499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
    Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
    Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular precision chemotherapy: overcoming resistance to targeted therapies?
    Burdach S
    Clin Cancer Res; 2014 Mar; 20(5):1064-6. PubMed ID: 24536061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.